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Background: Based on inconsistent sensory alterations demonstrated in cluster headache (CH), 
the aim of this study was to determine whether patients with CH develop sensory changes in 
the symptomatic side compared to the asymptomatic side.
Methods: Quantitative sensory testing (QST), including pressure pain threshold (PPT), tactile 
detection threshold (TDT), prick detection threshold (PDT), and two-point detection threshold 
(2PDT), was evaluated in 16 patients (seven women; age 41.9±6.8 years) with CH. Test sites 
included the first, second, and third divisions of the trigeminal nerve, cervical spine, and thenar 
eminence in the symptomatic and asymptomatic sides.
Results: The symptomatic side, compared to the asymptomatic side, presented significantly 
decreased PPT in the first (P=0.011; 423.81±174.05 kPa vs 480.13±214.99 kPa) and second 
(P=0.023; 288.88±140.80 kPa vs 326.38±137.33 kPa) divisions of the trigeminal nerve, 
significantly increased TDT in the first (P=0.002; 2.44±0.40 vs 1.74±0.24) and second 
(P=0.016; 1.92±0.34 vs 1.67±0.09) divisions, and increased 2PDT in the first division (P=0.004; 
18.13±4.70 mm vs 15.0±4.92 mm) and neck (P=0.007; 45.31±20.65 mm vs 38.44±16.10 mm).
Conclusion: These results support the prior evidence suggesting a specific pattern of 
alteration of sensory function with alterations in the symptomatic side compared to the asymp-
tomatic side.
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Introduction
Cluster headache (CH) is a primary headache disorder, which is classified as trigeminal 
autonomic cephalalgias (TACs).1 The characteristic symptoms are strictly unilateral 
headache, lasting from 15 to 180 minutes, usually involving the regions related to the 
first division of the trigeminal nerve, accompanied by ipsilateral autonomic features 
such as lacrimation, conjunctival injection, rhinorrhea, ptosis, miosis, or periorbital 
edema. Although CH is the most common primary TAC, its prevalence in the general 
population is about 0.1%.2
The pathophysiology of CH is not completely known.3 Clinical characteristics of 
CH suggest the involvement of the hypothalamus.4,5 Several studies have evidenced 
the activation of the suprachiasmatic nucleus of the hypothalamus in CH.6 Moreover, 
during the attack, a secondary activation of the trigemino-autonomic reflex has been 
demonstrated, probably through a hypothalamic trigeminal pathway, leading to the 
cranial autonomic features of CH.7,8 This includes the peripheral nerve fibers that 
innervate the pain-producing cranial vessels and dura mater and the centrally project-
ing fibers that synapse in the trigeminocervical complex.9
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Repetitive activity in afferent fibers produced by CH 
may induce plastic alterations in somatosensory synaptic 
processing. Sensory disturbances including hypersensitive 
responses to mechanical, thermal, and electrical stimulation 
have been consistently shown to be a feature of headache 
patients, being associated with augmented central nervous 
system pain-processing mechanisms.10 Sensory changes have 
also been shown to be associated with poor prognosis in dif-
ferent pain conditions including CH.11 Thus, several authors 
have emphasized the importance of an accurate neurological 
evaluation in patients with CH.12,13
Quantitative sensory testing (QST) is a valid and reliable 
tool to evaluate somatosensory function and may be useful 
in characterizing patients with trigeminal pain disorders.14,15 
QST provides information to illuminate the underlying 
mechanisms of CH.16
It has been proposed that CH may only affect certain 
aspects of sensory function following a specific pattern.8 
However, previous evidence studying specific sensory 
changes in sensory function has offered inconsistent results. 
Ellrich et al11 evidenced a significant reduction in pressure 
pain in the periorbital region of the symptomatic side com-
pared to the contralateral asymptomatic side of CH patients. 
Similarly, Coppola et al17 demonstrated lower pain thresholds 
on the symptomatic side compared to the asymptomatic side 
in episodic CH patients during the bout. On the other hand, 
Ashkenazi and Young18 found no evidence of specific sen-
sory disturbances in CH. Ladda et al19 measured mechanical 
thresholds of the cheeks and the back of the hands in CH 
patients and found that the side of the body had no influence 
on the sensory perception and pain thresholds.
Based on the documented activation of the trigeminocervi-
cal system in CH and the controversy of previous literature 
about the specificity of mechanical sensory changes produced 
by CH, our study had a double objective: first, to determine 
whether patients with CH develop sensory changes to 
mechanical stimuli in the symptomatic side compared to the 
asymptomatic side; second, to investigate whether a specific 
pattern of sensory alteration is produced depending on the 
locations where the CH is experienced. We hypothesized that 
patients with CH would demonstrate altered sensory thresh-
olds to mechanical stimuli in the symptomatic side compared 
to the asymptomatic side and the pattern of sensory alterations 
would depend on the locations where the CH is experienced.
Methods
The study was approved by the local ethics committee 
(Comité Ético de Investigación Clínica de Aragón) and was 
conducted in accordance with the Declaration of Helsinki. 
All participants were unpaid volunteers and gave their writ-
ten informed consent before participation. The protocol was 
carried out in the facilities of the Faculty of Health Sciences, 
University of Zaragoza. The data for this study were collected 
during 2013–2016.
Participants
Eligible patients were older than 18 years with a clinical 
diagnosis of CH by a neurologist following the International 
Classification of Headache Disorders, third edition (ICHD-3). 
Participants were excluded if they presented any contraindi-
cation to QST or were unable to understand instructions or 
communicate with researchers.
The sample consisted of nine (56.3%) men and seven 
(43.8%) women with a mean age of 41.9 (SD=6.8) years. 
The average intensity of CH was 9.50 (SD=0.78) points on 
a visual analog scale (0–10 points) with an average dura-
tion of 77.5 (SD=55.0) minutes. Ten (62.5%) patients had 
episodic CH (in remission of more than 3 months), and six 
(37.5%) had chronic CH. Regarding the lateralization of 
pain, nine (56.3%) patients had right CH and seven (43.8%) 
left CH. The average age at the onset of the first CH attack 
was 27.4 (SD=8.2) years with a mean duration of illness of 
13.4 (SD=10.7) years. The area related to the first division 
of the trigeminal nerve was the most frequently symptomatic 
(100.0%) followed by the area related to the second division 
of the trigeminal nerve (31.3% for main symptoms; 43.8% 
for shadows) and the area related to the third division of the 
trigeminal nerve (25.0% and 31.3% like shadows; shadow 
is a low-level ipsilateral persistent headache that can be a 
precursor of a CH attack).
Measurements
First, participants were asked to complete a questionnaire 
with demographic and clinical data, including age, gender, 
height, weight, and characteristics of CH (location, intensity, 
frequency, duration, and past history). The location of the 
pain was recorded by the patient on a scheme of the human 
body. The painful area was categorized into three divisions 
of the trigeminal nerve.
QST was performed to quantitatively measure the 
mechanical sensory function. Different modalities of mechan-
ical stimuli were incorporated to provide an indirect measure 
of primary afferents that mediated both innocuous and painful 
sensation. This included pressure pain threshold (PPT), tactile 
detection threshold (TDT), prick detection threshold (PDT), 
and two-point detection threshold (2PDT).
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PPT was measured using a pressure algometer 
(Somedic AB, Farsta, Sweden) with a probe size of 1 cm2 
and application rate of 30 kPa/s in a perpendicular direction 
to the skin.20,21 The patients were instructed to press the button 
when the sensation under the probe changed from pressure 
to pressure and pain.22 Three measurements were performed 
at each site, and the geometric mean was used for further 
analysis. Test sites included bilaterally the first division of 
the trigeminal nerve (V1) on the forehead, second division 
of the trigeminal nerve (V2) on the cheek, third division of 
the trigeminal nerve (V3) on the jaw, cranium on the parietal 
bone, upper trapezius muscle, articular pillar of C2–C3, 
suboccipital muscles, and thenar eminence.
TDT and PDT were measured with a set of 20 calibrated 
Semmes–Weinstein monofilaments (Saehan, marking number 
1.65–6.65; force 0.005–447 g) delivering a precise amount of 
pressure.20,21 To determine TDT and PDT, the method of limits 
was used, following a standardized protocol of five ascending 
and descending series.14 In the ascending series, monofilaments 
were applied in increasing order of strength until the patient 
reported the presence of the stimulus. In the descending series, 
monofilaments were applied in decreasing order of strength 
until the patient no longer detected the stimulus. Using the 
method of limits with suprathreshold and infrathreshold 
values, the geometrical mean was calculated. The number 
indicated in the monofilament was registered, corresponding 
to a logarithmic function of the applied force in grams.20,21 For 
TDT, the patient, with closed eyes, was instructed to indicate 
the detection of the touch of a monofilament. For PDT, the 
patient was instructed to indicate when the tactile sensation 
of the monofilament changed to sensation of prick. TDT and 
PDT were measured bilaterally on V1 (forehead), V2 (cheek), 
V3 (jaw), cervical spine (on the sternocleidomastoid muscle), 
ear (between lobule and tragus), and thenar eminence.
For 2PDT, a digital caliper (Mitutoyo) was used.23,24 
To determine 2PDT, the method of limits was used, following 
a standardized protocol.25 The application was repeated 
five times, in ascending and descending order, obtaining a 
series of suprathreshold and infrathreshold values that were 
used to calculate a geometric mean. The separation of the 
two jaws of the caliper was modified by 5 mm. The patient, 
with closed eyes, was instructed to indicate “one” or “two” 
depending on the tactile points detected.23 This measure 
was performed bilaterally on V1 (forehead), V2 (cheek), V3 
(jaw), cervical spine (on the sternocleidomastoid muscle), 
and thenar eminence.
QST was administered by the same specially trained 
researcher who was blinded to the symptomatic side.
statistical analyses
The statistical analysis was performed with SPSS 20.0 (IBM 
Corporation, Armonk, NY, USA) for Windows. Categorical 
variables were summarized with frequencies. Normally 
distributed continuous variables are presented with mean, 
SD, and range, and in the case of nonnormality, median, and 
range were used. Categorical variables were compared using 
the chi-squared test, and continuous variables were compared 
using Wilcoxon signed-rank test for related samples and 
Mann–Whitney U test and Kruskal–Wallis tests for indepen-
dent samples or Student’s t-test depending on the normality 
of the data. To evaluate the associations between QST and 
clinical and demographic characteristics of CH patients, 
Spearman correlation coefficient was calculated. The level 
of significance was set at P=0.05.
Results
Sixteen patients with CH diagnosed by neurologists on the 
basis of International Headache Society (IHS) criteria were 
recruited via advertisement. All patients met the selection 
criteria and were included in the study. Table 1 summarizes 
the baseline demographic and clinical data.
The results of mechanical sensory thresholds are pre-
sented in Table 2. The symptomatic side presented signifi-
cantly lower PPT in V1 (423.81 kPa, SD=174.05) and V2 
(288.80 kPa, SD=174.05) areas compared to the asymptom-
atic side (480.13 kPa, SD=214.99; 326.38 kPa, SD=137.33; 
P=0.011 and P=0.023). With regard to the TDT, the symp-
tomatic side showed significantly higher values in the V1 
(2.42, SD=0.40) and V2 (1.92, SD=0.34) areas compared 
to the asymptomatic side (1.74, SD=0.24; 1.67, SD=0.09; 
P=0.002 and P=0.016). No statistically significant difference 
between the symptomatic and asymptomatic side was found 
for PDT. The 2PDT was significantly higher in the symptom-
atic side compared to the asymptomatic side in the V1 area 
(18.13 mm, SD=4.70; 15.0 mm, SD=4.92; P=0.004) and in the 
neck (45.31 mm, SD=20.65; 38.44 mm, SD=16.10; P=0.007).
Tables 3 and 4 summarize the mechanical sensory thresh-
olds in the symptomatic side of patients depending on the 
presence of symptoms in V2 and V3 areas, respectively. The 
only statistically significant difference found was a higher 
PPT in the cranium of patients who did not present any symp-
toms (656.00 kPa [SD=92.86]) in the V2 region compared 
to those who had symptoms (420.40 kPa [SD=185.93]) or 
shadows (358.43 kPa [SD=155.59]) in V2 (P=0.034).
No statistically significant correlation of clinical 
relevance was found between the variables of interest: 
mechanical sensory thresholds (PPT, TDT, PDT, and 2PDT), 


























Yes, shadows 5 31.3
No 7 43.8
 Mean (SD) Median Minimum Maximum
age (years) 41.9 (6.8) 42.0 28.0 56.0
height (m) 1.73 (0.09) 1.74 1.60 1.80
Weight (kg) 78.94 (11.32) 79.50 60.0 103.0
BMi (kg/m2) 26.45 (3.63) 25.87 21.3 34.1
Vas (0–10) 9.50 (0.78) 9.95 7.60 10.0
Duration of a ch attack (minutes) 77.5 (55.0) 60.0 10.0 180.0
Time from the first CH (years) 13.4 (10.7) 9.0 1.0 35.0
age at the onset of ch (years) 27.4 (8.2) 28.0 15.0 41.0
Abbreviations: BMI, body mass index; CH, cluster headache; VAS, visual analog scale; V1, first division of the trigeminal nerve; V2, second division of the trigeminal nerve; 
V3, third division of the trigeminal nerve.
demographic and clinical data (age, gender, height, weight, 
and characteristics of CH).
Discussion
Altered mechanical sensory thresholds were found in the 
symptomatic side compared to the asymptomatic side of CH 
patients, with decreased PPT in V1 and V2, increased TDT 
in V1 and V2, and 2PDT in V1 and neck. Our results reflect 
lateralized pathological variation in the trigeminocervical 
system in CH patients.
The characteristics of our sample are similar to those 
in the previous literature. Previous demographic studies 
have reported that CH is more prevalent in men than 
women with ratios ranging from 1.3:1 to 7:1.26,27 As in our 
sample, episodic CH is more common than chronic CH.28 
Regarding pain location, right-sided pain has been shown 
to be predominant in CH in previous studies with the distri-
bution of the first division of the trigeminal nerve being the 
most frequent, followed by the second and third divisions 
as in our sample.26,27
Although it has been proposed that CH may only affect 
certain aspects of sensory function following a specific 
pattern, previous evidence studying specific changes in 
mechanical sensory function has offered conflicting results.8 
The results of the present study indicate that patients with CH 
evidence mechanical sensory alterations in the symptomatic 
side compared to the asymptomatic side. A significant 
reduction in PPT was evidenced in V1 (P=0.011) and 
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Table 2 Descriptive data (mean, sD, median, and range) and comparative analysis (P-value) for QsT comparing symptomatic and 
asymptomatic sides
Variables Symptomatic side Asymptomatic side P-value
PPT (kPa)
V1 423.81 (174.05)/400 (165–774) 480.13 (214.99)/466 (178–865) 0.011*
V2 288.88 (140.80)/311 (54–579) 326.38 (137.33)/365 (146–532) 0.023*
V3 259.63 (96.90)/285 (105–418) 284.63 (138.50)/285 (104–535) 0.127
cranium 452.19 (190.11)/474 (163–779) 467.25 (223.79)/449 (155–1,029) 0.605
Upper trapezius muscle 359.31 (194.36)/316 (84–772) 377.88 (210.31)/323.00 (96–732) 0.352
c2–c3 facet joint 324.94 (139.59)/352 (137–560) 346.81 (174.52)/364 (108–633) 0.535
suboccipital muscles 375.94 (160.48)/398 (143–627) 413.31 (169.39)/436 (151–715) 0.056
Thenar eminence 553.69 (257.65)/525.00 (244–1,009) 609.81 (249.79)/641 (188–978) 0.088
TDT
V1 2.42 (0.40)/2.44 (1.65–3.22) 1.74 (0.24)/1.65 (1.65–2.40) 0.002**
V2 1.92 (0.34)/1.65 (1.54–2.40) 1.67 (0.09)/1.65 (1.65–2.01) 0.016*
V3 1.93 (0.40)/1.65 (1.65–2.83) 1.74 (0.24)/1.65 (1.65–2.36) 0.068
ear 1.72 (0.19)/1.65 (1.65–2.36) 1.65 (0.00)/1.65 (1.65–1.65) 0.180
Neck 1.97 (0.39)/1.65 (1.65–2.64) 1.79 (0.27)/1.65 (1.65–2.44) 0.073
Thenar eminence 2.56 (0.33)/2.44 (2.36–3.61) 2.56 (0.32)/2.44 (2.36–3.61) 0.891
PDT
V1 4.40 (0.90)/4.56 (1.65–6.10) 4.38 (0.55)/4.17 (3.61–6.10) 0.440
V2 4.40 (0.46)/4.31 (3.84–5.88) 4.38 (0.59)/4.24 (3.84–6.45) 0.892
V3 4.35 (0.46)/4.24 (3.84–5.88) 4.39 (0.51)/4.31 (3.84–6.10) 0.180
ear 4.58 (0.63)/4.56 (3.61–6.55) 4.56 (0.61)/4.56 (3.61–6.55) 0.715
Neck 4.59 (0.65)/4.65 (3.61–6.55) 4.59 (0.66)/4.56 (3.84–6.55) 1.000
Thenar eminence 4.69 (0.39)/4.56 (4.08–5.88) 4.72 (0.44)/4.56 (4.08–6.10) 0.465
2PDT (mm)
V1 18.13 (4.70)/20 (10–25) 15.0 (4.92)/15 (5–20) 0.004**
V2 10.16 (4.96)/10 (5–20) 10.47 (3.90)/10 (5–15) 0.670
V3 14.06 (3.28)/15 (10–20) 12.97 (3.79)/15 (5–15) 0.149
Neck 45.31 (20.65)/40 (15–95) 38.44 (16.10)/35 (10–90) 0.007**
Thenar eminence 13.28 (2.37)/15 (10–15) 13.12 (2.14)/15 (10–15) 0.564
Notes: *Level of significance, P,0.05. **Level of significance, P,0.001.
Abbreviations: 2PDT, two-point detection threshold; PDT, prick detection threshold; PPT, pressure pain threshold; QsT, quantitative sensory testing; TDT, tactile 
detection threshold; V1, first division of the trigeminal nerve; V2, second division of the trigeminal nerve; V3, third division of the trigeminal nerve.
V2 areas (P=0.023) in the symptomatic side compared to the 
asymptomatic side in CH patients. These results support pre-
vious evidence of Ellrich et al11 and Coppola et al17 indicating 
a reduction in PPT in the symptomatic side compared to the 
asymptomatic side of 25 and 18 CH patients, respectively. 
However, Ladda et al19 found bilaterally increased thresholds 
in 16 CH patients, with no side influence, and not restricted 
to the trigeminal innervation, but were also on the back of 
the hands. Regarding TDT, the present study found higher 
values in V1 (P=0.002) and V2 (P=0.016) of the symptomatic 
side, indicating features of hypoesthesia in the symptom-
atic regions of V1 and V2. In the same line, Ashkenaz and 
Young18 evidenced mechanical sensory alterations in six out 
of 10 patients with CH, but found no evidence of specific 
mechanical sensory disturbances in the symptomatic side 
compared to the asymptomatic side. Ladda et al19 found no 
differences between the symptomatic and asymptomatic 
sides. Nevertheless, test sites evaluated by Ladda et al19 are 
limited to the cheek (V2) and the back of the hands, but V1 
area was not evaluated. According to the pain distribution in 
patients with CH, the evaluation of sensory function of the 
territory innervated by V1 may be of greater clinical value. 
The absence of significant differences between the symptom-
atic and asymptomatic side in PDT in our study supports the 
results of Ashkenaz and Young.18 This lack of differences may 
reflect the specificity of pathophysiological changes in CH, 





Table 3 Descriptive data (mean, sD, median, and range) and comparative analysis (P-value) for QsT in the symptomatic side comparing 
patients without symptoms in V2, with shadows in V2, and with symptoms in V2
Variables Patients without symptoms  
in V2 (n=4)
Patients with shadows  
in V2 (n=7)




V1 530.00 (105.48)/532 (400–655) 331.43 (123.41)/364 (165–515) 468.20 (231.81)/400 (247–774) 0.149
V2 436.50 (108.26)/423 (321–579) 239.29 (85.85)/212 (149–365) 240.20 (159.49)/301 (54–403) 0.069
V3 345.50 (66.51)/342 (280–418) 207.76 (74.32)/197 (105–301) 264.20 (106.85)/301 (146–395) 0.114
cranium 656.00 (92.86)/644 (557–779) 358.43 (155.59)/380 (163–547) 420.40 (185.93)/432 (236–676) 0.034*
Upper trapezius muscle 508.50 (191.77)/475 (312–772) 280.00 (94.59)/250 (183–451) 351.00 (259.44)/307 (84–684) 0.181
c2–c3 facet joint 448.25 (113.32)/462 (309–560) 252.43 (127.88)/167 (137–432) 327.80 (120.37)/381 (179–456) 0.081
suboccipital muscles 515.50 (88.40)/522 (403–615) 322.43 (165.23)/298 (143–627) 339.20 (153.58)/395 (163–497) 0.092
Thenar eminence 744.00 (275.61)/759 (448–1,009) 445.14 (257.44)/294 (244–939) 553.10 (189.00)/508 (413–876) 0.114
TDT
V1 2.35 (0.56)/2.36 (1.65–3.03) 2.42 (0.45)/2.44 (1.65–3.22) 2.50 (0.19)/2.44 (2.36–2.83) 0.498
V2 1.74 (0.18)/1.65 (1.65–2.01) 1.93 (0.36)/1.65 (1.65–2.40) 2.08 (0.39)/2.36 (1.65–2.36) 0.404
V3 2.10 (0.34)/2.18 (1.65–2.36) 1.93 (0.49)/1.65 (1.65–2.83) 1.79 (0.32)/1.65 (1.65–2.36) 0.421
ear 1.83 (0.36)/1.65 (1.65–2.36) 1.70 (0.14)/1.65 (1.65–2.01) 1.65 (0.00)/1.65 (1.65–1.65) 0.510
Neck 1.65 (0.00)/1.65 (1.65–1.65) 2.06 (0.42)/2.01 (1.65–2.64) 2.09 (0.40)/2.36 (1.65–2.44) 0.171
Thenar eminence 2.73 (0.59)/2.44 (2.44–3.61) 2.57 (0.25)/2.44 (2.36–3.01) 2.42 (0.04)/2.44 (2.36–2.44) 0.421
PDT
V1 4.05 (1.62)/4.74 (1.65–5.07) 4.26 (0.21)/4.17 (4.08–4.56) 4.89 (0.75)/4.56 (4.17–6.10) 0.131
V2 4.26 (0.36)/4.32 (3.84–4.56) 4.35 (0.22)/4.31 (4.08–4.56) 4.57 (0.75)/4.17 (4.08–5.88) 0.849
V3 4.22 (0.30)/4.24 (3.84–4.56) 4.28 (0.22)/4.31 (4.08–4.56) 4.55 (0.77)/4.17 (4.08–5.88) 0.948
ear 4.64 (0.38)/4.65 (4.17–5.07) 4.45 (0.38)/4.56 (3.61–4.74) 4.71 (1.05)/4.17 (4.08–6.55) 0.542
Neck 4.49 (0.29)/4.52 (4.17–4.74) 4.40 (0.47)/4.56 (3.61–4.74) 4.92 (1.00)/4.74 (4.08–6.55) 0.652
Thenar eminence 4.49 (0.13)/4.56 (4.31–4.56) 4.74 (0.20)/4.74 (4.56–5.07) 4.76 (0.67)/4.56 (4.08–5.88) 0.201
2PDT (mm)
V1 18.13 (2.39)/15 (15–20) 18.21 (5.53)/15 (10–25) 18.00 (5.70)/20 (10–25) 0.998
V2 10.00 (4.08)/10 (5–15) 10.36 (5.48)/10 (5–20) 10.00 (5.86)/10 (5–20) 0.973
V3 13.75 (4.79)/10 (10–20) 12.86 (2.67)/15 (10–15) 16.00 (2.24)/15 (15–20) 0.241
Neck 53.13 (27.03)/50 (25–90) 37.14 (11.76)/40 (15–55) 50.50 (25.15)/40 (35–95) 0.456
Thenar eminence 13.75 (2.50)/15 (10–15) 12.50 (2.50)/15 (10–15) 14.00 (2.23)/15 (10–15) 0.458
Note: *Level of significance, P,0.05.
Abbreviations: 2PDT, two-point detection threshold; PDT, prick detection threshold; PPT, pressure pain threshold; QsT, quantitative sensory testing; TDT, tactile 
detection threshold; V1, first division of the trigeminal nerve; V2, second division of the trigeminal nerve; V3, third division of the trigeminal nerve.
which would not affect the nerve fibers examined with PDT. 
Finally, regarding 2PDT, according to our knowledge, this is 
the first study to evaluate 2PDT in CH population. The results 
indicate higher 2PDT in V1 (P=0.004) and neck (P=0.007), 
which may reflect a decrease in the density of tactile receptors 
in these symptomatic regions, or even an alteration in some 
level of sensory processing. In any case, these results have 
to be contrasted with future research.
The examination of sensory function in patients with 
CH may be a very useful clinical tool. Baseline deficits of 
mechanical sensory function support a subclinical neuropathy 
that have previously been demonstrated to be predictive of 
poor prognosis in different clinical subgroups including CH.11 
This could allow to detect those patients who are going to 
become chronic before it happens with the purpose of taking 
preventive measures.
The most commonly reported location of CH is under 
the distribution of V1, mostly occurring behind the eye, in 
the periorbital region or in the temple. Areas related to V2 
or V3 are less frequent.26,27 Mechanical sensitivity patterns 
of patients with symptoms, shadows or without symptoms in 
V2 and V3, respectively, were compared. Despite the stag-
gered tendency in patients with symptoms and shadows in 
V2 and V3 to present lower PPT and higher DTT, especially 
in that region, when compared to patients with asymptomatic 
V2 and V3 regions, statistical significance was not reached 
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Table 4 Descriptive data (mean, sD, median, and range) and comparative analysis (P-value) for QsT in the symptomatic side comparing 
patients without symptoms in V3, with shadows in V3, and with symptoms in V3
Variables Patients without symptoms  
in V3 (n=7)
Patients with shadows  
in V3 (n=5)




V1 424.00 (166.26)/400 (165–655) 374.40 (114.13)/393 (198–515) 485.25 (264.02)/460 (247–774) 0.816
V2 352.29 (143.38)/356 (152–579) 262.20 (91.15)/269 (149–365) 211.25 (168.31)/194 (54–403) 0.289
V3 285.86 (107.30)/299 (105–418) 229.80 (70.77)/245 (143–301) 251.00 (118.58)/232 (146–395) 0.599
cranium 514.14 (205.91)/557 (163–779) 393.20 (158.55)/435 (164–547) 417.50 (214.56)/379 (236–676) 0.594
Upper trapezius muscle 394.71 (198.92)/312 (204–772) 307.60 (100.32)/320 (183–451) 362.00 (298.22/340 (84–684) 0.842
c2–c3 facet joint 357.86 (160.85)/401 (144.560) 291.20 (133.74)/324 (137–432) 309.50 (130.72)/302 (179–456) 0.653
suboccipital muscles 422.71 (142.62)/403 (204–615) 351.00 (190–461)/382 (143–627) 325.25 (173.64)/321 (163–497) 0.473
Thenar eminence 580.29 (297.37)/547 (245–1,009) 515.40 (278.42)/543 (244–939) 555.00 (218.20)/466 (413–876) 0.783
TDT
V1 2.37 (0.40)/2.36 (1.65–3.03) 2.44 (0.56)/2.44 (1.54–3.22) 2.52 (0.21)/2.44 (2.36–2.83) 0.421
V2 1.80 (0.28)/1.65 (1.65–2.36) 2.04 (0.37)/2.14 (1.65–2.44) 2.01 (0.41)/2.00 (1.65–2.36) 0.414
V3 1.90 (0.34)/1.65 (1.65–2.36) 2.04 (0.55)/1.65 (1.65–2.83) 1.83 (0.36)/1.65 (1.65–2.36) 0.743
ear 1.75 (0.27)/1.65 (1.65–2.36) 1.72 (0.16)/1.65 (1.65–2.01) 1.65 (0.00)/1.65 (1.65–1.65) 0.690
Neck 1.86 (0.37)/1.65 (1.65–2.44) 2.08 (0.45)/2.01 (1.65–2.64) 2.01 (0.41)/2.01 (1.65–2.36) 0.553
Thenar eminence 2.60 (0.45)/2.44 (2.36–3.61) 2.63 (0.27)/2.44 (2.44–3.01) 2.42 (0.04)/2.44 (2.36–2.44) 0.265
PDT
V1 4.15 (1.16)/4.56 (1.65–5.07) 4.31 (0.23)/4.17 (4.08–4.56) 4.98 (0.84)/4.82 (4.17–6.10) 0.290
V2 4.23 (0.27)/4.17 (3.84–4.56) 4.42 (0.22)/4.56 (4.08–4.56) 4.67 (0.83)/4.36 (4.08–5.88) 0.449
V3 4.19 (0.23)/4.17 (3.84–4.56) 4.32 (0.24)/4.31 (4.08–4.56) 4.67 (0.83)/4.36 (4.08–5.88) 0.541
ear 4.40 (0.48)/4.56 (3.61–5.07) 4.60 (0.08)/4.56 (4.56–4.74) 4.86 (1.14)/4.36 (4.17–6.55) 0.692
Neck 4.34 (0.43)/4.31 (3.61–4.74) 4.49 (0.37)/4.56 (3.84–4.74) 5.13 (1.02)/4.91 (4.15–6.55) 0.251
Thenar eminence 4.55 (0.13)/4.56 (4.31–4.74) 4.77 (0.23)/4.74 (4.56–5.07) 4.82 (0.76)/4.65 (4.08–5.88) 0.274
2PDT (mm)
V1 16.07 (3.49)/15 (10–20) 20.50 (4.74)/20 (15–25) 18.75 (6.29)/20 (10–25) 0.252
V2 9.29 (3.13)/10 (5–15) 11.00 (6.52)/10 (5–20) 10.63 (6.57)/10 (5–20) 0.969
V3 13.57 (3.78)/15 (10–20) 13.00 (2.73)/15 (10–15) 16.25 (2.50)/15 (15–20) 0.285
Neck 43.21 (23.97)/40 (15–90) 41.50 (7.83)/40 (35–55) 53.75 (27.80)/45 (35–95) 0.788
Thenar eminence 13.57 (2.44)/15 (10–15) 12.50 (2.50)/15 (10–15) 13.75 (2.50)/15 (10–15) 0.605
Abbreviations: 2PDT, two-point detection threshold; PDT, prick detection threshold; PPT, pressure pain threshold; QsT, quantitative sensory testing; TDT, tactile 
detection threshold; V1, first division of the trigeminal nerve; V2, second division of the trigeminal nerve; V3, third division of the trigeminal nerve.
except for PPT in the cranium (P=0.034). It is possible that 
the important tendency to evidence lower PPT and higher 
DTT in the specific symptomatic (or shadows) area did not 
reach statistical significance due to the small sample size 
of each subgroup. To the best of our knowledge, this is 
the first study that addresses this issue. Larger studies can 
perhaps be powered to detect subtle changes in mechanical 
sensory function depending on the specific symptomatic area. 
Previous studies have also evidenced that sensory alterations 
also seem to be determined by the temporal profile of the 
headache.29,30 Future studies should take into account not 
only the location of pain but also the intensity and temporal 
profile of the headache in CH patients.
Previous studies that had found bilateral mechanical 
sensory alterations not restricted to the territory of the 
trigeminal innervation suggested that a central process is 
responsible for these changes.19 The results of the pres-
ent study, where specific mechanical sensory changes 
have been found in the symptomatic side compared to the 
asymptomatic side, are interpreted as a sign of secondary 
sensitization of pain-processing second-order neurons within 
the trigeminocervical nucleus.29 The role of the trigeminal 
nerve in CH is indicated both by the increased concentrations 
of calcitonin gene-related peptide in the ipsilateral jugular 
vein during attacks and by the pain improvement after 
surgical lesioning of this nerve.7,31 Nevertheless, although 





trigeminal system activation is necessary for a CH attack, it 
is not sufficient on its own to produce CH.32 The evidence 
regarding the debate about peripheral vs central origin of pain 
in CH indicates that the central component plays a major part 
in generating the pain.4 Neuroimaging studies have confirmed 
the hypothalamic involvement in CH and have prompted 
the suggestion that the posterior hypothalamus was the 
CH generator.5 Evidence shows that the hypothalamus affects 
craniofacial region through an activation of the trigeminal 
system by a direct two-way connection between the posterior 
hypothalamus and the trigeminocervical nucleus through 
trigeminohypothalamic tract.33,34
Nevertheless, the current evidence shows that, although 
the hypothalamus is a key area for the pathophysiology of 
primary CH, we should probably move beyond thinking in 
terms of a single trigger zone and consider a hypothalamic 
activation of the pain matrix, involving cognitive, affective, 
and autonomic functions.4
This study had several limitations. First, the study lacked 
diagnostic validation. Even though all study participants had 
a clinical diagnosis of CH by a neurologist, specialists can 
still mistake one TAC for another. Second, clinical features 
were collected retrospectively compared to prospective data 
collection using headache diaries. For the survey questions, an 
inherent recall bias may have potentially occurred. Neverthe-
less, CH is a severe and excruciating headache disorder mak-
ing difficult not to correctly remember episodes. In addition, 
some participants usually kept a record of their CH attacks in 
a headache diary. Moreover, QST was performed to quantita-
tively measure mechanical sensory function, but we must be 
aware that QST is a quasi-objective measurement, combining 
objective measures with patient reports of sensory detection. 
This subjective component involves a risk of respondent bias. 
In any case, QST is a noninvasive psychophysiological test 
that can be used in a clinical setting to quantify neurological 
function of both small- and large-fiber nerves.14 Unlike 
excitability studies, QST assesses small-fiber function as 
well to better capture symptoms such as pain.35 Furthermore, 
QST allows the measurement of subclinical neurological 
changes early on to identify patients most likely to become 
chronic sufferers.11 Finally, the relatively small sample size 
limits the generalizability of the results. Larger studies are 
needed to validate these findings.
Conclusion
This study is the first to investigate mechanical sensory 
function in CH patients throughout the entire craniofacial 
region: in the three divisions of the trigeminal nerve 
(V1, V2, and V3), neck (superficial cervical plexus), and 
ear (trigeminal and facial nerves), including a control region 
(hand). The results of the present study showed decreased 
PPT and increased TDT in V1 and V2 of the symptomatic 
side associated with increased 2PDT in V1 and neck of the 
symptomatic side, supporting prior evidence that suggested a 
specific pattern of alteration of mechanical sensory function.
This study is the first attempt to evaluate specific mechan-
ical sensory changes in the symptomatic side depending on 
the symptomatic area in a sample of CH patients. Despite 
the tendency in patients with symptoms and shadows in V2 
and V3 to present lower PPT and higher DTT compared to 
patients with asymptomatic V2 and V3 regions, statistical 
significance was not reached. Future studies with larger 
samples are needed to further elucidate this issue.
clinical implications
•	 Sensory changes have been shown to be associated 
with poor prognosis in different pain conditions 
including CH.
•	 QST is a valid and reliable tool to evaluate somatosensory 
function and is useful in characterizing patients 
with CH.
•	 CH patients evidence altered mechanical sensory 
thresholds in the symptomatic side compared to the 
asymptomatic side.
•	 Somatosensory alterations indicate a lateralized 
pathological variation in the trigeminocervical system 
in CH patients.
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